Akeso

Ivonescimab, a PD-1/VEGF bispecific antibody, achieved a 48% reduction in progression-free survival risk compared to chemotherapy in EGFR-mutated NSCLC patients.

AstraZeneca is negotiating with Summit Therapeutics for a potential $15 billion licensing deal for ivonescimab, an experimental lung cancer drug that has shown promising results in late-stage trials.

Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.

• Pfizer has completed a record-breaking $6 billion acquisition deal with Chinese biopharmaceutical company 3SBio, energizing China's innovative drug industry and potentially driving further valuations upward. • RemeGen successfully raised HK$796 million through a premium placement, demonstrating strong investor confidence following the successful out-licensing of its RC18 asset. • The transactions highlight the growing momentum in China's biotech sector, with 3SBio's valuation expected to continue rising while competitor Akeso may face downward pressure. • China's 11th batch of national Volume-Based Procurement (VBP) rules are expected to include optimizations balancing competitive bidding prices with drug quality standards.

Summit Therapeutics reported statistically significant improvement in progression-free survival for ivonescimab plus chemotherapy versus BeiGene's Tevimbra combination in advanced squamous non-small cell lung cancer.

Akeso has received FDA approval for its first internally developed cancer therapeutic, marking a significant milestone for the Chinese biopharmaceutical company's expansion into the US market.

Summit Therapeutics and Akeso's bispecific antibody ivonescimab demonstrated superior progression-free survival compared to BeiGene's tislelizumab in squamous non-small cell lung cancer patients, adding to previous positive results against Merck's Keytruda.

Akeso announced positive Phase 3 results for ivonescimab, a novel PD-1/VEGF bispecific antibody, demonstrating superior tumor progression control when combined with chemotherapy compared to PD-1 inhibitor plus chemotherapy in lung cancer patients.

BNT327, a bispecific antibody targeting both PD-L1 and VEGF-A, demonstrated an 85.4% confirmed response rate when combined with chemotherapy in extensive-stage small cell lung cancer patients.

DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options.